Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development

Sonia M. Vallabh, Chloe K. Nobuhara, Franc Llorens, Inga Zerr, Piero Parchi, Sabina Capellari, Eric Kuhn, Jacob Klickstein, Jiri G. Safar, Flavia C. Nery, Kathryn J. Swoboda, Michael D. Geschwind, Henrik Zetterberg, Steven E. Arnold, Eric Vallabh Minikel, Stuart L. Schreiber

Research output: Contribution to journalArticle

Abstract

Reduction of native prion protein (PrP) levels in the brain is an attractive strategy for the treatment or prevention of human prion disease. Clinical development of any PrP-reducing therapeutic will require an appropriate pharmacodynamic biomarker: a practical and robust method for quantifying PrP, and reliably demonstrating its reduction in the central nervous system (CNS) of a living patient. Here we evaluate the potential of ELISA-based quantification of human PrP in human cerebrospinal fluid (CSF) to serve as a biomarker for PrP-reducing therapeutics. We show that CSF PrP is highly sensitive to plastic adsorption during handling and storage, but its loss can be minimized by the addition of detergent. We find that blood contamination does not affect CSF PrP levels, and that CSF PrP and hemoglobin are uncorrelated, together suggesting that CSF PrP is CNS derived, supporting its relevance for monitoring the tissue of interest and in keeping with high PrP abundance in brain relative to blood. In a cohort with controlled sample handling, CSF PrP exhibits good within-subject test–retest reliability (mean coefficient of variation, 13% in samples collected 8–11 wk apart), a sufficiently stable baseline to allow therapeutically meaningful reductions in brain PrP to be readily detected in CSF. Together, these findings supply a method for monitoring the effect of a PrP-reducing drug in the CNS, and will facilitate development of prion disease therapeutics with this mechanism of action.

Original languageEnglish
Pages (from-to)7793-7798
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume116
Issue number16
DOIs
Publication statusPublished - Apr 16 2019

Keywords

  • Biomarker
  • Cerebrospinal fluid
  • Creutzfeldt-Jakob disease
  • Human prion disease
  • Prion protein

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development'. Together they form a unique fingerprint.

  • Cite this

    Vallabh, S. M., Nobuhara, C. K., Llorens, F., Zerr, I., Parchi, P., Capellari, S., Kuhn, E., Klickstein, J., Safar, J. G., Nery, F. C., Swoboda, K. J., Geschwind, M. D., Zetterberg, H., Arnold, S. E., Minikel, E. V., & Schreiber, S. L. (2019). Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development. Proceedings of the National Academy of Sciences of the United States of America, 116(16), 7793-7798. https://doi.org/10.1073/pnas.1901947116